View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
Simen Mortensen
  • Simen Mortensen

NRC Group (Hold, TP: NOK4.00) - No signs of margin recovery

As expected, Q3 EPS was close to zero, with still-weak EBIT margins following the ETM project write-downs in Q2. The 2024 guidance was unchanged, for a negative adj. EBIT margin of 0.9–1.5%, but positive in 2025 (at least 2%) and 5%+ longer-term. While we see significant upside potential if NRC reaches the 5% target, its poor track record means we are still cautious about Q4–Q1, for which we expect EPS to again be close to zero. We reiterate our HOLD, but have raised our target price to NOK4 (3....

ABGSC Construct. & Real Estate Research ... (+3)
  • ABGSC Construct. & Real Estate Research
  • Bengt Jonassen
  • Njål Kleiven
ABGSC Construct. & Real Estate Research ... (+3)
  • ABGSC Construct. & Real Estate Research
  • Bengt Jonassen
  • Njål Kleiven
Patrik Ling
  • Patrik Ling

Elekta (Hold, TP: SEK69.00) - Still in ‘wait and see’ mode

During its Q1 call, Elekta indicated that H1 would be weaker than H2, and we believe this is reflected by consensus. For Q2, we forecast sales growth of c-5% YOY and organic growth of c-1% YOY. We expect order intake of cSEK4.9bn, broadly in line with consensus, and that the book-to-bill in Q2 should remain well above 1x. We are still cautious regarding Elekta’s longer-term performance, and reiterate our HOLD, while we have lowered our target price to SEK69 (76).

ABGSC Healthcare Research ... (+2)
  • ABGSC Healthcare Research
  • Sten Gustafsson
ABGSC Construct. & Real Estate Research ... (+3)
  • ABGSC Construct. & Real Estate Research
  • Bengt Jonassen
  • Njål Kleiven

Ambea AB: 7 directors

Seven Directors at Ambea AB sold/sold after exercising options 131,142 shares at between 97.000SEK and 99.500SEK. The significance rating of the trade was 55/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the com...

ABGSC Healthcare Research ... (+2)
  • ABGSC Healthcare Research
  • Morten Larsen
Rune Majlund Dahl
  • Rune Majlund Dahl

GN Group (Buy, TP: DKK230.00) - Looking for an upturn in Enterprise

Q3 sales missed, owing to Enterprise and Gaming & Consumer performing below expectations, while EBITA was strong at DKK553m (c5.1% above consensus). The 2024 guidance was cut for organic growth to 1–2%, maintained for a 12–13% EBITA margin, and raised for FCF to DKK1.1bn+. With flat growth in headsets for two consecutive quarters, offset by a speakerphone decline, we now forecast -3% organic growth in 2024 (-2% in Q4). We reiterate our BUY and DKK230 target price.

Oliver Metzger
  • Oliver Metzger

GN Store Nord : Q3 2023 review – Lower end of guidance range for Enter...

>Q3 review - Miss on top line, EBITA as expected, beat on EPS level - GN Store Nord achieved Q3 2024 revenues of DKK 4,164m (-6.3% y-o-y, -6%/-5% vs ODDO BHF/consensus). Q3 EBITA reached DKK 553m (+18.7% y-o-y, margin 13.3%), which was in line with our and the consensus’ expectations. EPS reached DKK 1.86, well ahead of our DKK 1.44 and consensus’ DKK 1.34.GN Hearing continues its strong market outperformance - GN Hearing’s Q3 revenues of DKK 1,725m (...

ABGSC Healthcare Research ... (+2)
  • ABGSC Healthcare Research
  • Morten Larsen
Karl-Johan Bonnevier
  • Karl-Johan Bonnevier

Ambea (Buy, TP: SEK120.00) - Margin approaching 9.5% already

Q3 showed continued solid revenue, earnings and FCF generation, with Ambea close to reaching its medium-term >9.5% EBITA margin target (Q3 LTM 9.4%). We see a strong case, given: 1) the robust demand outlook combined with an asset-light, cash-generating model; 2) renewed execution on bolt-on acquisitions and dividends/share buybacks; and 3) an attractive valuation at 2024–2026e FCF yields of 9–11%. We reiterate our BUY and have raised our target price to SEK120 (110).

 PRESS RELEASE

Interim Report Q3 2024: Further margin expansion and strong cash flow ...

Interim Report Q3 2024: Further margin expansion and strong cash flow despite mixed growth across divisions Highlights The Hearing division continued to gain significant market share leading to 10% organic revenue growth, while the divisional profit margin increased by 5.9 percentage points to 34.8%The Enterprise division was negatively impacted by sell-in pressure due to economic growth challenges in parts of Central Europe, while North America and Rest of World continued its stabilization. Overall, organic revenue growth ended at -7%, while sell-out growth was -3%. Despite the topline...

 PRESS RELEASE

Update of financial guidance for 2024

Update of financial guidance for 2024 GN has throughout the year increased its earnings power and cash flow generation, leading to an upgrade of the guidance on free cash flow excl. M&A to “DKK >1,100 million” and a confirmation of the EBITA margin guidance of “12 to 13%”. Following a somewhat softer market development than earlier anticipated for Enterprise and Gaming, GN adjusts its organic revenue growth guidance to “1% to 2%” Financial guidance for 2024 Organic revenue growthReported EBITA marginFree cash flow excl. M&A (DKK million)UpdatedPriorConfirmedPriorUpdatedPrior1% to 2%2% to 6...

Rune Majlund Dahl
  • Rune Majlund Dahl

GN Group (Buy, TP: DKK230.00) - Adding company consensus

GN Group recently released company consensus. We forecast Q3 organic revenue growth of 0.4% YOY (consensus -0.2%) and an EBITA margin of 12.5% (consensus 12.0%). We expect still-strong traction of Nexia, but Enterprise to decline organically YOY. We expect unchanged 2024 guidance for 2–6% organic revenue growth and a 12–13% EBITA margin. We reiterate our BUY and DKK230 target price.

I.A.R. Systems Group: 3 directors

A director at I.A.R. Systems Group bought 25,000 shares at 118.000SEK and the significance rating of the trade was 53/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years...

ABGSC Healthcare Research ... (+2)
  • ABGSC Healthcare Research
  • Morten Larsen
Rune Majlund Dahl
  • Rune Majlund Dahl

GN Group (Buy, TP: DKK230.00) - Still expecting traction on Nexia

Sonova’s launches were the main focus at the EUHA conference. While we are positive on the integration of AI technology, we question whether the larger size and reduced battery time will be well received by customers. We still expect to see traction for Nexia, and AI in the next platform. For Q3, we are slightly above post-Q2 company consensus and expect an unchanged 2024 guidance. We reiterate our BUY and DKK230 target price.

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch